{
  "resourceType" : "ResearchStudy",
  "id" : "2022-500014-26-00",
  "meta" : {
    "lastUpdated" : "2025-01-07T00:00:00.000Z",
    "profile" : ["https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-researchstudy"]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Narratif généré : ResearchStudy 2022-500014-26-00</b></p><a name=\"2022-500014-26-00\"> </a><a name=\"hc2022-500014-26-00\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Dernière mise à jour : 2025-01-07 00:00:00+0000</p><p style=\"margin-bottom: 0px\">Profil: <a href=\"StructureDefinition-eclaire-researchstudy.html\">ECLAIREResearchStudy</a></p></div><p><b>ECLAIREReviewDate</b>: 2025-01-07 00:00:00+0000</p><p><b>ECLAIRETherapeuticArea</b>: Maladies [C] - Tumeurs [C04]</p><blockquote><p><b>ECLAIREassociatedPartyR5</b></p><ul><li>name: F. Hoffmann-La Roche AG</li><li>role: <span title=\"Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-party-role-code-system lead-sponsor}\">lead-sponsor</span></li><li>party: <a href=\"https://simplifier.net/resolve?scope=hl7.fhir.uv.xver-r5.r4@0.0.1-snapshot-1&amp;canonical=http://hl7.org/fhir/uv/xver/Organization/2022-500014-26-00-primary-sponsor\">Reference to primary sponsor</a></li></ul></blockquote><p><b>identifier</b>: 2022-500014-26-00\u00a0(use:\u00a0official,\u00a0)</p><p><b>title</b>: UNE ETUDE DE PHASE III, RANDOMISEE, OUVERTE, EVALUANT L'EFFICACITE ET LA SECURITE DU GIREDESTRANT EN ASSOCIATION AVEC PHESGO PAR RAPPORT A PHESGO APRES UN TRAITEMENT D'INDUCTION PAR PHESGO+TAXANE CHEZ DES PATIENTES ATTEINTES D'UN CANCER DU SEIN LOCALEMENT AVANCÉ OU METASTATIQUE, HER2-POSITIF ET POSITIF AUX RECEPTEURS DES OESTROGENES, QUI N'A PAS ETE TRAITE AU PREALABLE.</p><p><b>status</b>: Active</p><p><b>phase</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/research-study-phase phase-3}\">Phase 3</span></p><p><b>category</b>: <span title=\"Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-regulation-code-code-system REG536}\">REG536 (CTIS)</span>, <span title=\"Codes:{https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-reglementation-precision-code-system study-ctis}\">un essai clinique (CTIS)</span></p><p><b>condition</b>: <span title=\"Codes:\">Cancer du sein localement avancé, non résécable ou métastatique (MBC)</span>, <span title=\"Codes:{https://www.meddra.org 10065430}\">Cancer du sein HER2 positif</span>, <span title=\"Codes:{https://www.meddra.org 10070575}\">Cancer du sein à récepteurs aux oestrogènes positifs</span></p><p><b>contact</b>: ph: 41616881111(Work),<a href=\"mailto:EU.CTSubmissions@roche.com\">EU.CTSubmissions@roche.com</a>, ph: -unknown-(Work),<a href=\"mailto:null\"/></p><p><b>location</b>: <span title=\"Codes:{urn:iso:std:iso:3166 BE}\">Belgium</span>, <span title=\"Codes:{urn:iso:std:iso:3166 DE}\">Germany</span>, <span title=\"Codes:{urn:iso:std:iso:3166 ES}\">Spain</span>, <span title=\"Codes:{urn:iso:std:iso:3166 FR}\">France</span>, <span title=\"Codes:{urn:iso:std:iso:3166 HU}\">Hungary</span>, <span title=\"Codes:{urn:iso:std:iso:3166 IT}\">Italy</span>, <span title=\"Codes:{urn:iso:std:iso:3166 PL}\">Poland</span>, <span title=\"Codes:{urn:iso:std:iso:3166 PT}\">Portugal</span></p><p><b>enrollment</b>: <a href=\"https://simplifier.net/resolve?scope=hl7.fhir.uv.xver-r5.r4@0.0.1-snapshot-1&amp;canonical=http://hl7.org/fhir/uv/xver/Group/2022-500014-26-00-enrollment-group\">Reference to group detailing study characteristics</a></p></div>"
  },
  "extension" : [{
    "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-review-date",
    "valueInstant" : "2025-01-07T00:00:00.000Z"
  },
  {
    "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-therapeutic-area",
    "valueString" : "Maladies [C] - Tumeurs [C04]"
  },
  {
    "extension" : [{
      "url" : "name",
      "valueString" : "F. Hoffmann-La Roche AG"
    },
    {
      "url" : "role",
      "valueCodeableConcept" : {
        "coding" : [{
          "system" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-party-role-code-system",
          "version" : "0.3.0",
          "code" : "lead-sponsor",
          "display" : "lead-sponsor"
        }]
      }
    },
    {
      "url" : "party",
      "valueReference" : {
        "reference" : "Organization/2022-500014-26-00-primary-sponsor",
        "type" : "Organization",
        "display" : "Reference to primary sponsor"
      }
    }],
    "url" : "http://hl7.org/fhir/5.0/StructureDefinition/extension-ResearchStudy.associatedParty"
  }],
  "identifier" : [{
    "use" : "official",
    "value" : "2022-500014-26-00",
    "assigner" : {
      "reference" : "Organization/ctis",
      "type" : "Organization",
      "display" : "Reference to primary assigner"
    }
  }],
  "title" : "UNE ETUDE DE PHASE III, RANDOMISEE, OUVERTE, EVALUANT L'EFFICACITE ET LA SECURITE DU GIREDESTRANT EN ASSOCIATION AVEC PHESGO PAR RAPPORT A PHESGO APRES UN TRAITEMENT D'INDUCTION PAR PHESGO+TAXANE CHEZ DES PATIENTES ATTEINTES D'UN CANCER DU SEIN LOCALEMENT AVANCÉ OU METASTATIQUE, HER2-POSITIF ET POSITIF AUX RECEPTEURS DES OESTROGENES, QUI N'A PAS ETE TRAITE AU PREALABLE.",
  "status" : "active",
  "phase" : {
    "coding" : [{
      "system" : "http://terminology.hl7.org/CodeSystem/research-study-phase",
      "version" : "1.0.0",
      "code" : "phase-3",
      "display" : "Phase 3"
    }]
  },
  "category" : [{
    "coding" : [{
      "system" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-regulation-code-code-system",
      "version" : "0.3.0",
      "code" : "REG536",
      "display" : "REG536 (CTIS)"
    }]
  },
  {
    "coding" : [{
      "system" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-reglementation-precision-code-system",
      "version" : "0.3.0",
      "code" : "study-ctis",
      "display" : "un essai clinique (CTIS)"
    }]
  }],
  "condition" : [{
    "id" : "disease-condition-2022-500014-26-00",
    "text" : "Cancer du sein localement avancé, non résécable ou métastatique (MBC)"
  },
  {
    "id" : "meddra-condition-2022-500014-26-00-10065430",
    "coding" : [{
      "system" : "https://www.meddra.org",
      "version" : "3.0.0",
      "code" : "10065430",
      "display" : "Cancer du sein HER2 positif"
    }]
  },
  {
    "id" : "meddra-condition-2022-500014-26-00-10070575",
    "coding" : [{
      "system" : "https://www.meddra.org",
      "version" : "3.0.0",
      "code" : "10070575",
      "display" : "Cancer du sein à récepteurs aux oestrogènes positifs"
    }]
  }],
  "contact" : [{
    "extension" : [{
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name",
      "valueHumanName" : {
        "use" : "official",
        "family" : "Regulatory Data and Content Chapter",
        "given" : ["Clinical Trial Accountable"]
      }
    }],
    "telecom" : [{
      "system" : "phone",
      "value" : "41616881111",
      "use" : "work"
    },
    {
      "system" : "email",
      "value" : "EU.CTSubmissions@roche.com",
      "use" : "work"
    }]
  },
  {
    "extension" : [{
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name",
      "valueHumanName" : {
        "use" : "official"
      }
    },
    {
      "url" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type",
      "valueCodeableConcept" : {
        "coding" : [{
          "system" : "https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system",
          "version" : "0.3.0",
          "code" : "PUB",
          "display" : "Publique / Public"
        }]
      }
    }],
    "telecom" : [{
      "system" : "phone",
      "use" : "work"
    },
    {
      "system" : "email",
      "use" : "work"
    }]
  }],
  "location" : [{
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "BE",
      "display" : "Belgium"
    }]
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "DE",
      "display" : "Germany"
    }]
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "ES",
      "display" : "Spain"
    }]
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "FR",
      "display" : "France"
    }]
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "HU",
      "display" : "Hungary"
    }]
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "IT",
      "display" : "Italy"
    }]
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "PL",
      "display" : "Poland"
    }]
  },
  {
    "coding" : [{
      "system" : "urn:iso:std:iso:3166",
      "version" : "4.0.1",
      "code" : "PT",
      "display" : "Portugal"
    }]
  }],
  "enrollment" : [{
    "reference" : "Group/2022-500014-26-00-enrollment-group",
    "type" : "Group",
    "display" : "Reference to group detailing study characteristics"
  }]
}